Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.46 |
| ▸ | HTR3B | O95264 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5971931 | 0.84 | HTR6 (0.59) | HTR6CYP3A4LMNAKDM4EALDH1A1 | |
| SCHEMBL28920377 | 0.83 | HTR6 (0.65) | HTR6CYP3A4HTR3EHTR3BHTR3A | |
| SCHEMBL5971994 | 0.80 | HTR6 (0.50) | HTR6CYP3A4LMNAKDM4EALDH1A1 | |
| SCHEMBL5200370 | 0.80 | HTR6 (0.53) | HTR6CYP3A4THRBADRB1 | |
| SCHEMBL28920482 | 0.80 | HTR6 (0.61) | HTR6CYP3A4THRBHTR3EHTR3B | |
| SCHEMBL5200846 | 0.80 | HTR6 (0.67) | HTR6CYP3A4THRBHTR3EHTR3B | |
| SCHEMBL30091139 | 0.80 | HTR6 (0.61) | HTR6CYP3A4THRBHTR3EHTR3B | |
| SCHEMBL5202829 | 0.78 | HTR6 (0.57) | HTR6CYP3A4THRB | |
| SCHEMBL1136468 | 0.77 | HTR6 (0.64) | HTR6CYP3A4POLB | |
| SCHEMBL5972079 | 0.77 | HTR6 (0.53) | HTR6CYP3A4THRBLMNAHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556037-B1 | 4-PIPERAZINYL BENZENESULFONYL INDOLES WITH 5-HT6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2006-11-02 | — | — | EP | claimed |
| EP-1556037-A1 | 4-PIPERAZINYL BENZENESULFONYL INDOLES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-27 | — | — | EP | claimed |
| WO-2004035047-A1 | 4-PIPERAZINYL BENZENESULFONYL INDOLES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-29 | — | — | WO | claimed |
| EP-1556037-B1 | 4-PIPERAZINYL BENZENESULFONYL INDOLES WITH 5-HT6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2006-11-02 | — | — | EP | disclosed |
| US-7022708-B2 | 4-piperazinyl benzenesulfonyl indoles and uses thereof | ROCHE PALO ALTO LLC (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1556037-A1 | 4-PIPERAZINYL BENZENESULFONYL INDOLES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-27 | — | — | EP | disclosed |
| US-20040087593-A1 | 4-Piperazinyl benzenesulfonyl indoles and uses thereof | ROCHE PALO ALTO LLC | 2004-05-06 | — | — | US | disclosed |
| WO-2004035047-A1 | 4-PIPERAZINYL BENZENESULFONYL INDOLES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087593-A1 | 4-Piperazinyl benzenesulfonyl indoles and uses thereof | HTR6, HTR4, HTR5A | HTR6 1/4885CYP3A4 265/4885THRB 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.